Medscape is available in 5 Language Editions – Choose your Edition here.


Metabolic Neuropathy Treatment & Management

  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
Updated: Oct 27, 2014

Medical Care

The best medical care for patients with metabolic neuropathy is control of the underlying metabolic condition, which results in better control of the neuropathy.

  • Diabetic neuropathy: No pharmacologic treatment exists for moderately severe to severe diabetic peripheral neuropathy or other metabolic neuropathies. Only symptomatic treatments exist for pain and other conditions such as gastroparesis. However, control of hyperglycemia has been demonstrated to decrease progression of diabetic neuropathy.[22] This section discusses recent and ongoing studies, followed by a discussion of symptomatic treatment.
    • Insulin pump: Continuous infusion of insulin has been demonstrated to improve results of NCS. This treatment seems to benefit only patients with mild peripheral neuropathy associated with diabetes. Exercise caution to prevent severe hypoglycemic episodes.
    • Aldose reductase inhibitors: Recent meta-analysis of randomized controlled trials of aldose reductase inhibitors indicates that benefits of treatment have not been demonstrated conclusively in diabetic neuropathy.
    • Neurotrophic factors: Neurotrophic factors have been tested in animal models of diabetic neuropathy. Insulin growth factor (IGF) and NGF have yielded encouraging results in animal studies. However, in humans, only recombinant NGF has been tested in phase II clinical trials, and the initial results did not demonstrate major benefits.
    • Gangliosides: Gangliosides have been shown to promote improvement in sensation without changes in NCVs. A moratorium has been placed on their development because of significant adverse effects.
    • Linoleic acid: In patients with diabetes, conversion of linolic acid or its metabolite gamma linoleic acid (GLA) is impaired. A recent multicenter study using GLA for 1 year demonstrated clinical and neurophysiologic improvement.
    • Advanced glycosylation end products (AGE): AGE inhibitors have shown some value in treatment of peripheral neuropathy in rats. Human trials are pending.
    • Human intravenous immunoglobulin: Small open-label studies have demonstrated improvement in diabetic peripheral neuropathy, especially in neuropathies with asymmetric involvement (eg, diabetic lumbosacral radiculoplexopathy) with intravenous immunoglobulin. Further studies are necessary to draw definitive conclusions.
  • Symptomatic treatment of diabetic neuropathy
    • Gastroparesis: The first step is to attempt multiple small feedings. The amount of dietary fat should be decreased. Metoclopramide, which sensitizes tissue to the action of acetylcholine, stimulates the motility of the upper gastrointestinal tract. Cisapride, a prokinetic drug, is effective in some patients. If medications fail, jejunostomy may help.
    • Enteropathy: Stasis of bowel contents with bacterial overgrowth may contribute to diarrhea. Treatment with broad-spectrum antibiotics such as ampicillin or tetracycline is the initial therapy. Metronidazole may also be given. Anticholinergics may help in controlling diarrhea. Patients with poor digestion may benefit from a gluten-free diet.
    • Cystopathy: Patients with neurogenic bladder may not perceive when the bladder is full. Manual downward pressure of the bladder can help. Parasympathomimetic agents such as bethanechol also may be of help.
  • Treatment of painful neuropathy: The FDA has approved duloxetine hydrochloride, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), for the treatment of diabetic peripheral neuropathic pain. A recent study concerning neuropathic pain using the NNT approach (number of patients needed to treat to get a beneficial response) was published recently by Sindrup and Jensen.[23] This section reviews the drugs most often used to treat pain in peripheral neuropathies based on their approach.
    • Tricyclic antidepressants: Tricyclic antidepressants have been shown to be effective in treating painful diabetic neuropathy. Tricyclics act on the central nervous system, preventing the reuptake of norepinephrine and serotonin at synapses involved in pain inhibition. Benefits are unrelated to relief of depression. Amitriptyline and nortriptyline are used most commonly.
    • Selective antidepressants: Selective serotonin reuptake inhibitors (SSRIs) specifically inhibit presynaptic reuptake of serotonin but not noradrenaline. Paroxetine has been effective in painful diabetic neuropathy.
    • Ion channel blockers
      • Lidocaine: Lidocaine is a nonspecific sodium channel blocker. It relieves painful diabetic neuropathy in severe cases but is not convenient to administer since no oral form is available.
      • Mexiletine: Mexiletine is an oral analogue of lidocaine. It has been used at a dosage of 10 mg/kg, but clinical trials so far have shown equivocal results.
      • Phenytoin: Phenytoin blocks sodium channels nonspecifically and therefore reduces neuronal excitability in sensitized C-nociceptors. It has been demonstrated to be effective in neuropathic pain, but it suppresses insulin secretion and may precipitate hyperosmolar coma in patients with diabetes.
      • Carbamazepine: Carbamazepine is another nonspecific sodium channel blocker that has been effective in the treatment of painful diabetic neuropathy, but it is more useful in trigeminal neuralgia.
      • Gabapentin: Gabapentin is a novel anticonvulsant with an unknown mechanism of action, but it is believed to antagonize glutamate excitotoxicity. It has demonstrated effectiveness in neuropathic pain, but doses in clinical trials were as high as 3600 mg. Freeman et al performed a meta-analysis of 7 randomized, placebo-controlled trials that evaluated the efficacy and safety of pregabalin treatment of painful diabetic peripheral neuropathy.[25] Daily doses included 150, 300, and 600 mg/d, with dosing intervals of 2 or 3 times per day. Pregabalin was found to be effective for painful diabetic peripheral neuropathy at all doses and intervals, with the greatest and most rapid pain reduction seen in patients receiving pregabalin 600 mg/d divided into 2 or 3 doses.
      • Lamotrigine: Lamotrigine is a new anticonvulsant acting as a stabilizer in the slow inactivated conformation of a subtype of sodium channels, indirectly suppressing the neuronal release of glutamate. Studies in trigeminal neuralgia favor its use, but no studies have been reported in other neuropathic pain syndromes.
    • N -methyl-D-aspartate (NMDA) antagonists: Aspartate, an excitatory neurotransmitter, has been shown to play a role in the development of neuropathic pain. Its receptor is NMDA. NMDA antagonists have shown effectiveness when given intravenously for neuropathic pain (eg, ketamine). Other studies with another NMDA antagonist, dextromethorphan, have shown efficacy for neuropathic pain.
    • Opioids: Until recently, high controversy surrounded opioid use in neuropathic pain. However, recent studies have demonstrated its efficacy in different types of neuropathic pain. Tramadol is an analgesic drug probably acting over both monoaminergic and opioid mechanisms. The monoaminergic effect is shared with tricyclic antidepressants. Tolerance and dependence appear to be uncommon. Doses of 100-400 mg have been shown to be effective in diabetic neuropathic pain. Oxycodone and morphine have been tried in other neuropathic pain syndromes with good results. Risk of dependence remains an issue to consider, and these agents should not be given to individuals at risk of addiction.
    • Levodopa: Dopamine agonists inhibit noxious input to the spinal cord. Levodopa also has actions over noradrenergic receptors. One recent study showed benefit in polyneuropathic pain with 300 mg/d of levodopa.
    • Capsaicin: Capsaicin is an alkaloid substance derived from chilies. It depletes substance P from sensory nerves, causing chemodenervation. It has demonstrated effectiveness in several studies of diabetic neuropathic pain and in other types of neuropathic pain as well. It must be applied topically every 4 hours over the entire pain area. It causes a burning sensation, and applying it with gloves is advisable.
    • Miscellaneous: Several still unproven medical treatments are proposed for mitochondrial respiratory chain disorders, including drugs such as coenzyme Q10, menadione, vitamin E, ascorbic acid, N -acetylcysteine, riboflavin, succinate, L-carnitine, and dichloroacetate.

Surgical Care

See the list below:

  • Surgical release of entrapment neuropathy (CTS, ulnar neuropathy at the elbow, TTS)
  • Specialized surgical care of diabetic foot and foot ulcers, including vascular and plastic surgery evaluation
  • Jejunostomy for severe gastroparesis
  • Pancreatic islet transplants have been reported to improve diabetic neuropathy and pancreas-kidney transplantation in patients with diabetes and renal failure
  • Liver transplantation (may improve familial amyloid neuropathy)
  • Renal transplantation (may improve uremic neuropathy)


See the list below:

  • Nutrition or genetics consults, especially for patients with diabetes or metabolic neuropathies in childhood
  • General surgery for patients in whom transplant is considered
  • Plastic or vascular surgery for patients with diabetic foot ulceration or necrosis


See the list below:

  • Low-calorie diet in patients with diabetes
  • Modified lipid-intake diets for inherited conditions associated with alteration in lipid metabolism
  • Low-protein intake in chronic renal failure and in hepatic failure


No restrictions in activity are recommended for most of the metabolic neuropathies. However, some neuropathies in childhood can be triggered by exercise.

Contributor Information and Disclosures

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Milind J Kothari, DO Professor, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Penn State Milton S Hershey Medical Center

Milind J Kothari, DO is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Fernando Dangond, MD, and Luis Carlos Sanin, MD, to the development and writing of this article.

  1. Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am. 1997 Apr. 44(2):285-300. [Medline].

  2. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010 Aug. 10(4):276-82. [Medline].

  3. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999 Aug 30. 107(2B):2S-8S. [Medline].

  4. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2011 May-Jun. 25(3):159-67. [Medline].

  5. Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014 Nov. 14(11):541. [Medline].

  6. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999 Dec 10. 53(9):2113-21. [Medline].

  7. Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin. 1992 Aug. 10(3):783-807. [Medline].

  8. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab. 1977 Dec. 3(4):245-56. [Medline].

  9. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):9S-16S. [Medline].

  10. Chalk CH. Acquired peripheral neuropathy. Neurol Clin. 1997 Aug. 15(3):501-28. [Medline].

  11. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: WB Saunders Co; 1993.

  12. Comi G, Corbo M. Metabolic neuropathies. Curr Opin Neurol. 1998 Oct. 11(5):523-9. [Medline].

  13. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: WB Saunders Co; 1993. 1221.

  14. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):34S-42S. [Medline].

  15. Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid. 1995 Aug. 5(4):283-6. [Medline].

  16. Kyle RA. Monoclonal proteins in neuropathy. Neurol Clin. 1992 Aug. 10(3):713-34. [Medline].

  17. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9. 354(10):1021-30. [Medline].

  18. Simmons DN, Lisle DA, Linklater JM. Imaging of Peripheral Nerve Lesions in the Lower Limb. Techniques in Foot & Ankle Surgery. 2008/12. 7(4):224-237.

  19. Lisle DA, Johnstone SA. Usefulness of muscle denervation as an MRI sign of peripheral nerve pathology. Australas Radiol. 2007 Dec. 51(6):516-26. [Medline].

  20. Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry. 1998 Dec. 65(6):810-21. [Medline].

  21. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. 2008 Mar. 13(1):7-26. [Medline].

  22. Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013 Sep. 74(3):397-403. [Medline]. [Full Text].

  23. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999 Dec. 83(3):389-400. [Medline].

  24. Lagueny A. [Metabolic and nutritional neuropathies]. Rev Prat. 2000 Apr 1. 50(7):731-5. [Medline].

  25. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul. 31(7):1448-54. [Medline]. [Full Text].

  26. Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. 1999 Dec. 189(6):584-93. [Medline].

  27. Kaminski HJ, Ruff RL. Neurologic complications of endocrine diseases. Neurol Clin. 1989 Aug. 7(3):489-508. [Medline].

  28. Kluding PM, Pasnoor M, Singh R, D'Silva LJ, Yoo M, Billinger SA, et al. Safety of Aerobic Exercise in People With Diabetic Peripheral Neuropathy. Phys Ther. 2014 Oct 2. [Medline].

  29. Parry GJ. Management of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):27S-33S. [Medline].

Table 1. Symptoms and Signs of Peripheral Neuropathy*
Small-Fiber SensoryLarge-Fiber SensoryAutonomic
Burning painLoss of vibrationHeart rate changes
Cutaneous allodyniaProprioception lossPostural blood pressure change
ParesthesiasLoss of reflexesAbnormal sweating
Lancinating painSlowed NCVsGastroparesis
Loss pain/temperatureSensory ataxiaImpotence
Foot ulcersWeaknessAbnormal ejaculation
Visceral pain loss  
* Modified from Apfel, 1999.[14]
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.